TRIPLE THERAPY FOR EFFECTIVE MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE EXACERBATIONS AND REDUCTION OF CARDIOVASCULAR EVENTS

Abstract

Triple therapy to prevent exacerbations of chronic obstructive pulmonary disease (COPD) is associated with better patient health than monotherapy or dual therapy. The EROS trial evaluated the benefit of budesonide/glycopyrone/formoterol (BGF) triple therapy given immediately after a COPD exacerbation. This was a retrospective analysis of clinical data in COPD patients. The frequency of COPD exacerbations and health care costs were assessed depending on the timeliness of BGF administration after an experienced COPD exacerbation. Within 30 days, treatment with BGF has been shown to have the best effect in reducing future exacerbations and reducing healthcare expenditure associated with COPD. For every 30-day delay in treatment, there is a 5% increase in the risk of further exacerbations and healthcare expenditure. The direct relationship between COPD and cardiovascular events is also highlighted. Acute exacerbations of COPD increase the rate of cardiovascular events, which are highest immediately after the exacerbation and remain elevated one year later. After an exacerbation, there is a clear window of opportunity for rapid clinical intervention and treatment optimization to reduce this long-term risk of cardiovascular events. However, it is important to keep in mind the need to constantly assess risks and optimize treatment. Preventing COPD exacerbations can help reduce the risk of cardiovascular disease. Proactive disease management, including triple therapy, can help prevent COPD exacerbations and more rapid health deterioration in the future.